---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Somatostatin analogs"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Somatostatin analogs. Topics: Octreotide test, long-acting analogs, and off-label pasireotide for insulinoma: ENETS guidance; Risk of worsening hypoglycemia in metastatic insulinoma: ESMO guideline; Receptor expression, octreotide challenge, and pasireotide in insulinoma: clinical review; Octreotide response by somatostatin receptor subtype in insulinoma; 7 further topics. 11 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/somatostatin-analogs"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Somatostatin analogs

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Somatostatin Analogs

<a id="topic-2.2.2.1.5-1"></a>

### Octreotide test, long-acting analogs, and off-label pasireotide for insulinoma: ENETS guidance

> “SSA can reduce insulin levels and prevent hypoglycaemic episodes in patients with advanced insulinomas.”
> “As SSA also decrease glucagon secretion and SSTR expression can be limited in insulinomas, which could paradoxically aggravate hypoglycaemia, a trial with short-acting octreotide under close monitoring of glucose levels is advised [5, D]. After demonstration of a positive effect on glucose levels, long-acting release (LAR) octreotide or lanreotide can be initiated. In cases with advanced insulinoma with hypoglycaemia refractory to octreotide or lanreotide, the pan-somatostatin receptor-targeting pasireotide can be tried off-label.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.5-2"></a>

### Risk of worsening hypoglycemia in metastatic insulinoma: ESMO guideline

> “SSA should be used under surveillance for the risk of worsening hypoglycaemia.”

Source: [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

<a id="topic-2.2.2.1.5-3"></a>

### Receptor expression, octreotide challenge, and pasireotide in insulinoma: clinical review

> “Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas (81).”
> “SRLs can adequately suppress the pathologic insulin hypersecretion in patients with insulinomas that express SSTR2 (17, 70, 81, 82). A challenge with subcutaneous administration of the short-acting SRL octreotide, is generally recommended before switching to a long-acting formulation. This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression (81–84).”
> “In Cushing disease, acromegaly and in phase 2-3 studies in NET (including panNET), hyperglycemia (79%), and type 2 diabetes were important side effects observed with pasireotide because of its inhibitory effects on incretin release (86–92). However, until now, pasireotide has not been approved for the treatment of panNET. Anecdotal reports show successful control with pasireotide of hypoglycemia in patients with insulinoma (75, 93–97).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.5-4"></a>

### Octreotide response by somatostatin receptor subtype in insulinoma

> “Octreotide was effective on hypoglycaemia in 10/17 patients. Octreoscan scintigraphy detected 4/17 insulinomas. sst2A receptor was detected in 7/17 insulinomas and sst5 in 15/17 insulinomas.”
> “Octreotide is an effective treatment of hypoglycaemia in more than 50% of patients with insulinoma. Detection of responsive patients was better based on a positive short test with subcutaneous octreotide than on the results of Octreoscan scintigraphy.”

Source: [Vezzosi et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15879362/)

<a id="topic-2.2.2.1.5-5"></a>

### Long-term octreotide in endogenous hyperinsulinism not treated by surgery

> “Reasons for not undergoing surgery were: refusal (n = 3), old age with multiple diseases (n = 5), unlocalized insulinomas (n = 2), malignant unresectable insulinomas (n = 5), multiple insulinomas (n = 3) and diffuse beta-cell disease (n = 3). Hypoglycaemia was responsive to octreotide in 14 of the 21 patients.”
> “Subcutaneous octreotide treatment was prolonged for > 6 months (7-144 months, 67 +/- 47 months) in 11 responsive patients. No tachyphylaxis was observed. However, the octreotide dose had to be increased in two patients after 3 and 18 months, respectively. Only one patient suffered from symptomatic biliary lithiasis after 3 years of treatment.”

Source: [Vezzosi et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18031316/)

<a id="topic-2.2.2.1.5-6"></a>

### Pasireotide for insulinoma-associated hypoglycemia: systematic review of published cases

> “Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria.”
> “Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3).”

Source: [Vega-Beyhart et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40165498/)

<a id="topic-2.2.2.1.5-7"></a>

### Octreotide indications and glucose warning: octreotide long-acting prescribing information

> “SANDOSTATIN LAR DEPOT is a somatostatin analogue indicated for: Treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for: • Acromegaly (1.1) • Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors (1.2) • Profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors (1.3)”
> “Octreotide alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone (GH), which may result in hypoglycemia or hyperglycemia. Blood glucose levels should be monitored when SANDOSTATIN LAR DEPOT treatment is initiated, or when the dose is altered.”

Source: [Sandostatin LAR Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008s049lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

### Lanreotide antitumor indication and glucose warning: lanreotide prescribing information

> “SOMATULINE DEPOT is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.”
> “Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Hence, patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.”

Source: [Somatuline Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022074s032lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

### Pasireotide indication and hyperglycemia warning: pasireotide prescribing information

> “SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.”
> “Blood glucose elevations have been seen in healthy volunteers and patients treated with SIGNIFOR.”
> “Nearly all patients in the study, including those with normal glucose status at baseline, pre-diabetes, and diabetes, developed worsening glycemia in the first two weeks of treatment.”

Source: [Signifor prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/200677s012lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

### Octreotide in NICTH: clinical review

> “Diazoxide and octreotide have no role in NICTH.”
> “Octreotide, a nonspecific somatostatin analog, has been used unsuccessfully in multiple cases (39, 91).”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.5-11"></a>

### Octreotide among recovered and deceased patients with IGF-2-mediated NICTH

| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
| --- | --- | --- | --- | --- |
| Octreotide | “18 (7.7%)” | “9 (5.2%)” | “9 (17.6%)” | “.01” |

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

Additional sources: [Hendren et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29055143/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
